Oxysterols are intermediates in the development of bile acids, steroid hormones, vitamin D3, and other bioactive markers of inflammation and other disease states. Oxysterols—oxidized products of sterols—are bioactive intermediaries that are associated with certain diseases, and further research is required to understand their role in disease pathogenesis. Oxysterols have the potential to influence many conditions from cardiovascular diseases such as atherosclerosis, to Alzheimer’s disease, diabetes, and cancer. This suggests that further research and understanding of oxysterols may help to better understand these conditions.
A thorough understanding of a disease phenotype is crucial for effective treatment, and metabolomic research into the possible causes of a disease is the next step in the fight for disease prevention. Unfortunately, detecting and identifying oxysterols in untargeted metabolomics can be challenging, and custom assay development is a typical approach to quantifying specific analytes as part of wider research. Choosing an extensive targeted metabolomics provider can offer you confidence in routine quantitation of oxysterols for your research.
The Metabolon Oxysterol Targeted Panel measures 12 oxysterols and related sterols of biological significance. Our validated method of oxysterol detection and identification in human plasma samples may enable you to gain additional insights in your research—helping you to discern whether oxysterols are a significant biomarker for a disease state or inflammatory response within your study and whether their detection can potentially be used as a precursor for medical screening.
With over 20 years’ experience helping commercial and academic studies gain insights from metabolomic analyses and with over 2,000 citations in scientific journals, Metabolon is leading the way in applied metabolomics solutions worldwide. Quality is at the core of everything we do. All methods are developed and validated according to ISO 9001:2015 standards, so you can be confident in our ability to match your quality standards.
(Scroll left/right to see full table)
| LLOQa | |
|---|---|
| Metabolite | Plasma |
| 24-Hydroxycholesterol | 10.0 ng/mL |
| 27-Hydroxycholesterol | 20.0 ng/mL |
| Desmosterol | 100 ng/mL |
| 7-Dehydrocholesterol | 100 ng/mL |
| 8-Dehydrocholesterol | 25.0 ng/mL |
| Lathosterol | 200 ng/mL |
| 5α, 6α-Epoxycholesterol | 15.0 ng/mL |
| 4β-Hydroxycholesterol | 5.00 ng/mL |
| Cholesterol | 0.125 mg/mL |
| Lanosterol | 10.0 ng/mL |
| 5α, 6β-Dihydroxycholestanol | 10.0 ng/mL |
| 7α, 27-Dihydroxycholesterol | 10.0 ng/mL |
aLower Limit of Quantitation (LLOQ) varies for each sample type.
LC-MS/MS: Agilent 1290 UHPLC/Sciex QTrap 5500 and 6500+
(Scroll left/right to see full table)
| Sample Type | Sample Requirements |
|---|---|
| Plasma | ≥ 250 µL |
Others on request
Disclaimer: This panel is for Research Use Only and is not to be used for diagnostic purposes.
Our readily available or custom developed quantitative assays help you achieve your research and biomarker validation objectives with precise and fully validated methods. Our targeted assays and panels cover more than 1,000 metabolites and lipids across a wide range of biochemical classes, metabolic pathways, and physiological processes, and they can be customized to best fit any application.
Heart disease is a leading cause of death worldwide, and there are numerous factors that lead to this and other cardiovascular diseases (CVD). Metabolomics can illuminate cardiovascular disease at multiple levels. In preclinical studies, such as with cardiomyocytes or heart tissue from model organisms, understanding mitochondrial function, energetics, and redox status can drive critical insights into disease mechanisms. In human studies, metabolomics offers the opportunity to account for well-established CVD risk factors such as cholesterol and complex lipids, while simultaneously profiling thousands of other biochemicals in an unbiased fashion to enable the discovery of novel disease mechanisms and biomarkers.
The importance of inflammation in the development of multiple diseases- and health-related conditions including neurodegeneration, diabetes, cardiovascular disease, cancer, and inflammatory bowel disease is undisputed. Metabolomics can inform on inflammatory processes by providing a readout of the small molecules of an organism, tissue, biofluid, etc. This allows for direct molecular phenotyping of inflammation beyond the standard protein markers of typical assays. Metabolon offers several targeted assays, including oxysterols, fatty acids, kynurenine/tryptophan, and a range of others (central carbon, glucose tolerance, branched-chain amino acids, β-hydroxybutyrate) that can also inform on overall cardiovascular health that is often linked with inflammatory processes.
Dysregulated metabolism is essential for the growth and proliferation of individual cancer cells, but the physiology of the patient is as much a part of the equation as the tumor. Metabolomics can both identify cancer-specific drug targets and assess the patient’s phenotype more broadly, addressing key questions such as: Who will respond to the therapy? How can we expand the pool of responders? How can we predict adverse events? Overall, metabolomics informs decision-making and positions development programs for success by providing a functional readout of the molecular phenotype.
Diabetes is a serious metabolic condition affecting more than 37 million Americans and 460 million people worldwide according to the most recent report from the Centers for Disease Control. Despite being a worldwide epidemic, much remains unknown about individual risk factors for diabetes development, and research is currently being done to identify new and effective treatment for diabetes at all stages. By facilitating assessment of specific metabolic pathways impacted by diabetes, targeted metabolomics can be a critical tool used to identify biomarkers of disease development for early intervention and novel targets to control disease progression, as well for the development of new pharmaceuticals with specific mechanisms of action.
It is well-established that a low-carbohydrate, high-fat ketogenic diet (KD) can help treat refractory epilepsy, which affects more than a third of epileptic patients who don’t respond to existing anticonvulsive drugs. What scientists haven’t understood until recently is how this kind of diet translates to brain activity. The answer for this aspect of epilepsy lies in the gut microbiome. There are many other neurological disorders like Alzheimer’s disease, ALS, Parkinson’s disease, and more. While so much remains to be understood about brain science, we do know that metabolomics is uniquely poised to understand the brain because of the ability of metabolites, small molecules, to cross the blood-brain barrier providing unique insights.
Once you see the full value of metabolomics, the only remaining question is: who does it best? While many laboratories have metabolite profiling or analytical chemistry capabilities, comprehensive metabolomics technologies are extremely rare.
Accurate, unbiased metabolite identification across the entire metabolome introduces signal-to-noise challenges that very few labs are equipped to handle. Also, translating massive quantities of data into actionable information is slow, if not impossible, for most because proper interpretation takes two things that are in short supply: experience and a comprehensive database.
Using our robust platform and visualization tools, our experts are uniquely able to tell you more about your molecule and develop assay panels to help you zero in on the results you need.
Coverage
Ability to interrogate thousands of metabolites across diverse biochemical space, revealing new insights and opportunities
Comparability
Ability to integrate the data from different studies into the same dataset, in different geographies, among different patients over time
Competency
Ability to inform on proper study design, generate high‐quality data, derive biological insights, and make actionable recommendations
Capacity
Ability to process hundreds of thousands of samples quickly and cost‐efficiently to service rapidly growing demand
Request a quote for our services, get more information on sample types and handling procedures, request a letter of support, or submit a question about how metabolomics can advance your research.
Corporate Headquarters
617 Davis Drive, Suite 100
Morrisville, NC 27560
Mailing Address
P.O. Box 110407
Research Triangle Park, NC 27709
Phone
+1 (919) 572-1711
Fax
+1 (919) 572-1721
International Headquarters
Metabolon GmbH
Zeppelinstraße 3
85399 Hallbergmoos
Germany
